跳轉至內容
Merck
全部照片(1)

重要文件

SML3237

Sigma-Aldrich

G-5555

≥98% (HPLC)

同義詞:

8-(((2r,5r)-5-Amino-1,3-dioxan-2-yl)methyl)-6-(2-chloro-4-(6-methylpyridin-2-yl)phenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one, 8-[(trans -5-Amino-1,3-dioxan-2-yl)methyl]-6-[2-chloro-4-(6-methyl-2-pyridinyl)phenyl]-2-(methylamino)pyrido[2,3-d ]pyrimidin-7(8H )-one

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C25H25ClN6O3
CAS號碼:
分子量::
492.96
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/L, clear

儲存溫度

−20°C

一般說明

G-5555 is a selective p21-activated kinase (PAK1) inhibitor. In addition to this it also selectively inhibits eight kinases such as PAK2, PAK3, KHS1, lymphocyte-specific protein tyrosine kinase (LcK), Mammalian Ste20-like kinase 3 (MST3), Mammalian Ste20-like kinase 4 (MST4), salt-inducible kinase 2(SIK2), and Yeast Sps1/Ste20-related Kinase 1 (YSK1). G-5555 exhibits high stability and low human ether-à-go-go related gene (hERG) activity than other PAK inhibitors including FRAX1036.

生化/生理作用

G-5555 is an ATP site-targeting inhibitor against salt-inducible kinases, MST3/4, p21-activated kinase 1/2, YANK1/3, MAP2K5, MAP4K5 (% inhibition at 100 nM = 98.6/93.5/99.8 (SIK1/2/3), 85/99.5 (MST3/4), 95.6/87 (PAK1/2), 94.7/96.5 (YANK1/3); 87/MAP2K5, 83/MAP4K5) with good selectivity over other kinases. G-5555 downregulates MEK pS298 in EBC1 cells in cultures (IC50 = 69 nM) and in H292 NSCLC tumors in mice in vivo (25 mg/kg p.o.) with good oral availability (mice F = 80%, monkeys F = 72%).
G-5555 is an ATP site-targeting inhibitor against salt-inducible kinases, MST3/4, p21-activated kinase 1/2, YANK1/3, MAP2K5, MAP4K5 (% inhibition at 100 nM = 98.6/93.5/99.8 (SIK1/2/3), 85/99.5 (MST3/4), 95.6/87 (PAK1/2), 94.7/96.5 (YANK1/3); 87/MAP2K5, 83/MAP4K5) with good selectivity over other kinases. G-5555 downregulates MEK pS298 in EBC1 cells in cultures (IC50 = 69 nM) and in H292 NSCLC tumors in mice in vivo (25 mg/kg p.o.) with good oral availability (mice F = 80%, monkeys F = 72%). PAK1 plays a crucial role in cancer progression, inhibiting this protein has the potential to reduce cancer development. Therefore, G-5555 may be a promising candidate for oncology research.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Christina M Knippler et al.
Endocrine-related cancer, 26(8), 699-712 (2019-05-31)
The number of individuals who succumb to thyroid cancer has been increasing and those who are refractory to standard care have limited therapeutic options, highlighting the importance of developing new treatments for patients with aggressive forms of the disease. Mutational
Chudi O Ndubaku et al.
ACS medicinal chemistry letters, 6(12), 1241-1246 (2015-12-30)
Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the limitations of FRAX1036 (1) were chiefly associated with the highly basic amine it contained, we devised a mitigation strategy to
Roberta Tesch et al.
Journal of medicinal chemistry, 64(12), 8142-8160 (2021-06-05)
Salt-inducible kinases (SIKs) are key metabolic regulators. The imbalance in SIK function is associated with the development of diverse cancers, including breast, gastric, and ovarian cancers. Chemical tools to clarify the roles of SIK in different diseases are, however, sparse
Hai-Feng Qiao et al.
Journal of reproductive immunology, 140, 103129-103129 (2020-04-26)
The present study was meant for the discovery of the underlying functions of miR-485-5p in ovarian cancer concerning cisplatin resistance in vitro. RT-qPCR assessed the miR-485-5p expression in ovarian cancer cell lines, normal cells and cisplatin-resistant Cell line OVCA433-CR. After

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務